However, few studies have investigated the association between CLDN18.2 and HER2, PD-L1, and the tumour immune microenvironment in GC patients without prior preoperative anticancer treatment, including chemotherapy, radiotherapy, biotherapy, or immunotherapy. Here, ERBB2 is linked to gastric cancer.